合計 50 件の最近のインサイダー取引記録が記録されています Arrowhead Pharmaceuticals, Inc. (ARWR), 内訳は 13 件の買い および 33 件の売り. インサイダー買い総額は $963.33K インサイダー売り総額は $12.5M.
最近活動のある主要インサイダーには Hamilton James C, O'brien Patrick, Apel Daniel Joseph. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — ARWR
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2026-03-05 |
Hamilton James C |
Chief Medical Officer |
情報に基づく売り |
10,000 |
$64.19 |
$641.9K |
236,958 |
| 2026-01-06 |
O'brien Patrick |
COO |
贈与（送付） |
440 |
- |
- |
472,408 |
| 2026-01-06 |
Hamilton James C |
Chief Medical Officer |
RSU 付与（制限付株式） |
75,000 |
- |
- |
246,958 |
| 2026-01-06 |
Apel Daniel Joseph |
Chief Financial Officer |
RSU 付与（制限付株式） |
75,000 |
- |
- |
176,200 |
| 2026-01-05 |
O'brien Patrick |
COO |
情報に基づく売り |
46 |
$68.00 |
$3.13K |
474,908 |
| 2026-01-05 |
Hamilton James C |
Chief Medical Officer |
情報に基づく売り |
309 |
$68.00 |
$21.01K |
171,958 |
| 2026-01-02 |
Anzalone Christopher Richard |
Chief Executive Officer |
情報に基づく売り |
5,771 |
$66.39 |
$383.14K |
3,792,739 |
| 2025-12-31 |
O'brien Patrick |
COO |
贈与（送付） |
560 |
- |
- |
524,401 |
| 2025-12-29 |
Anzalone Christopher Richard |
Chief Executive Officer |
オプション行使（売却） |
16,545 |
$6.15 |
$101.75K |
- |
| 2025-12-26 |
Ferrari Mauro |
Director |
情報に基づく売り |
7,530 |
$70.00 |
$527.1K |
69,053 |
| 2025-12-22 |
Anzalone Christopher Richard |
Chief Executive Officer |
情報に基づく売り |
2,574 |
$68.85 |
$177.22K |
3,805,926 |
| 2025-12-19 |
Olukotun Adeoye Y |
Director |
情報に基づく売り |
827 |
$68.48 |
$56.63K |
33,600 |
| 2025-12-19 |
Anzalone Christopher Richard |
Chief Executive Officer |
情報に基づく売り |
1,319 |
$68.48 |
$90.33K |
3,818,512 |
| 2025-12-19 |
Waddill William D. |
Director |
情報に基づく売り |
500 |
$68.53 |
$34.27K |
56,563 |
| 2025-12-19 |
Vakiener Victoria |
Director |
情報に基づく売り |
1,960 |
$68.39 |
$134.04K |
35,723 |
| 2025-12-17 |
Anzalone Christopher Richard |
Chief Executive Officer |
情報に基づく売り |
1,981 |
$66.30 |
$131.34K |
3,831,957 |
| 2025-12-16 |
Anzalone Christopher Richard |
Chief Executive Officer |
情報に基づく売り |
3,221 |
$67.87 |
$218.61K |
3,916,957 |
| 2025-12-16 |
Ingram Douglas S |
Director |
RSU 付与（制限付株式） |
7,819 |
- |
- |
46,215 |
| 2025-12-16 |
Olukotun Adeoye Y |
Director |
RSU 付与（制限付株式） |
7,819 |
- |
- |
43,600 |
| 2025-12-16 |
Perry Michael S |
Director |
RSU 付与（制限付株式） |
7,819 |
- |
- |
123,059 |
| 2025-12-16 |
Ferrari Mauro |
Director |
RSU 付与（制限付株式） |
7,819 |
- |
- |
76,583 |
| 2025-12-16 |
Waddill William D. |
Director |
RSU 付与（制限付株式） |
7,819 |
- |
- |
64,930 |
| 2025-12-16 |
Lu Hongbo |
Director |
RSU 付与（制限付株式） |
7,819 |
- |
- |
54,982 |
| 2025-12-16 |
Vakiener Victoria |
Director |
RSU 付与（制限付株式） |
7,819 |
- |
- |
45,763 |
| 2025-12-15 |
Anzalone Christopher Richard |
Chief Executive Officer |
情報に基づく売り |
8,147 |
$69.96 |
$569.96K |
3,971,255 |
| 2025-12-12 |
Anzalone Christopher Richard |
Chief Executive Officer |
RSU 付与（制限付株式） |
180,000 |
- |
- |
4,101,255 |
| 2025-12-05 |
Perry Michael S |
Director |
情報に基づく売り |
16,250 |
$61.03 |
$991.74K |
115,240 |
| 2025-11-28 |
Ferrari Mauro |
Director |
情報に基づく売り |
8,750 |
$56.39 |
$493.41K |
68,764 |
| 2025-10-01 |
Hamilton James C |
Chief Medical Officer |
情報に基づく売り |
20,000 |
$35.00 |
$700K |
212,122 |
| 2025-09-12 |
Hamilton James C |
Chief Medical Officer |
情報に基づく売り |
15,000 |
$30.00 |
$450K |
232,122 |
| 2025-09-02 |
Hamilton James C |
Chief Medical Officer |
情報に基づく売り |
15,000 |
$25.00 |
$375K |
247,122 |
| 2025-08-15 |
Hamilton James C |
Chief Medical Officer |
情報に基づく売り |
9,389 |
$20.00 |
$187.78K |
262,122 |
| 2025-08-13 |
Hamilton James C |
Chief Medical Officer |
情報に基づく売り |
611 |
$20.00 |
$12.22K |
271,511 |
| 2025-04-15 |
Apel Daniel Joseph |
Chief Financial Officer |
不明 |
- |
- |
- |
101,200 |
| 2025-04-11 |
Anzalone Christopher Richard |
Chief Executive Officer |
情報に基づく売り |
50,800 |
$11.49 |
$583.69K |
3,921,255 |
| 2025-04-10 |
Anzalone Christopher Richard |
Chief Executive Officer |
情報に基づく売り |
50,000 |
$10.87 |
$543.5K |
3,972,055 |
| 2025-04-09 |
Anzalone Christopher Richard |
Chief Executive Officer |
情報に基づく売り |
1,617 |
$11.76 |
$19.02K |
4,022,055 |
| 2025-03-13 |
Anzalone Christopher Richard |
Chief Executive Officer |
情報に基づく売り |
51,425 |
$15.07 |
$774.97K |
4,062,377 |
| 2025-03-04 |
Anzalone Christopher Richard |
Chief Executive Officer |
情報に基づく売り |
133,333 |
$17.02 |
$2.27M |
3,773,802 |
| 2025-03-03 |
Anzalone Christopher Richard |
Chief Executive Officer |
オプション行使（売却） |
133,333 |
$7.75 |
$1.03M |
51,726 |
| 2025-02-07 |
Anzalone Christopher Richard |
Chief Executive Officer |
RSU 付与（制限付株式） |
9,550 |
$20.10 |
$191.96K |
3,773,802 |
| 2025-02-06 |
Ingram Douglas S |
Director |
不明 |
- |
- |
- |
- |
| 2025-02-06 |
Ingram Douglas S |
Director |
RSU 付与（制限付株式） |
38,396 |
$20.09 |
$771.38K |
38,396 |
| 2025-01-23 |
Olukotun Adeoye Y |
Director |
情報に基づく売り |
959 |
$21.00 |
$20.14K |
35,781 |
| 2025-01-07 |
Myszkowski Kenneth Allen |
Chief Financial Officer |
情報に基づく売り |
10,000 |
$19.69 |
$196.9K |
455,433 |
| 2025-01-07 |
O'brien Patrick |
COO and General Counsel |
情報に基づく売り |
8,000 |
$19.69 |
$157.52K |
527,201 |
| 2025-01-06 |
Myszkowski Kenneth Allen |
Chief Financial Officer |
情報に基づく売り |
9,402 |
$20.10 |
$188.98K |
473,433 |
| 2025-01-06 |
O'brien Patrick |
COO and General Counsel |
情報に基づく売り |
9,526 |
$20.10 |
$191.47K |
535,201 |
| 2025-01-06 |
Hamilton James C |
Chief Discovery/trans Medicine |
情報に基づく売り |
10,971 |
$20.11 |
$220.63K |
272,122 |
| 2025-01-04 |
Myszkowski Kenneth Allen |
Chief Financial Officer |
RSU 付与（制限付株式） |
100,000 |
- |
- |
500,600 |
■ 情報付き — 公開市場取引（最も重要）
■ 情報なし（買い） — 報酬・オプション行使・転換
■ 情報なし（売り） — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効
